rSIFN-co Among Healthy Subjects and Subjects With Mild or Asymptomatic COVID-19
Status:
Recruiting
Trial end date:
2023-02-28
Target enrollment:
Participant gender:
Summary
This is a phase II pilot, international, multicenter, randomized, double-blind,
placebo-controlled study that aims to evaluate the safety and preliminary efficacy of
rSIFN-co nasal spray in healthy subjects in close contact with confirmed COVID-19 case(s) as
well as subjects with mild or asymptomatic COVID-19.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Sichuan Huiyang Life Science and Technology Corporation